Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS2 | Q9H2K2 | 3/20 | 0.54 |
| ▸ | GABRA1 | P14867 | 8/20 | 0.43 |
| ▸ | GABRB2 | P47870 | 8/20 | 0.43 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.41 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.41 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.38 |
| ▸ | TNKS | O95271 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31351924 | 0.79 | TNKS2 (0.71) | TNKS2GABRA1GABRB2GABRA5GABRA3 | |
| SCHEMBL8081097 | 0.79 | TNKS2 (0.71) | TNKS2GABRA1GABRB2GABRA5GABRA3 | |
| SCHEMBL31351925 | 0.79 | TNKS2 (0.71) | TNKS2GABRA1GABRB2GABRA5GABRA3 | |
| SCHEMBL6022953 | 0.78 | TNKS2 (0.56) | TNKS2CNR1CNR2 | |
| SCHEMBL25382404 | 0.75 | TNKS2 (0.65) | TNKS2GABRA1GABRB2GABRA5GABRA3 | |
| SCHEMBL20399476 | 0.74 | GABRA1 (0.49) | TNKS2GABRA1GABRB2GABRA5GABRA3 | |
| SCHEMBL16978333 | 0.73 | CNR1 (0.49) | GABRA1GABRB2CNR1CNR2ALOX5 | |
| SCHEMBL20399293 | 0.72 | GABRA1 (0.47) | GABRA1GABRB2CNR1CNR2 | |
| SCHEMBL8120125 | 0.70 | CNR1 (0.57) | TNKS2GABRA1GABRB2GABRA5GABRA3 | |
| SCHEMBL8133536 | 0.70 | MEN1 (0.45) | GABRA1GABRB2CNR1CNR2ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11174343-B2 | Bioderived biphenyl-containing compounds and their conversion to polymers and macromonomers | ALLIANCE FOR SUSTAINABLE ENERGY, LLC (US) | 2021-11-16 | — | — | US | disclosed |
| US-20200262972-A1 | BIODERIVED BIPHENYL-CONTAINING COMPOUNDS AND THEIR CONVERSION TO POLYMERS AND MACROMONOMERS | Alliance for Energy Innovation, LLC | 2020-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200262972-A1 | BIODERIVED BIPHENYL-CONTAINING COMPOUNDS AND THEIR CONVERSION TO POLYMERS AND MACROMONOMERS | CYP1B1, PHB2, PCBP1 | TNKS2 1576/4885GABRA1 1533/4885GABRB2 477/4885 |
| US-11174343-B2 | Bioderived biphenyl-containing compounds and their conversion to polymers and macromonomers | CYP1B1, PHB2, PCBP1 | TNKS2 1576/4885GABRA1 1533/4885GABRB2 477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.